Home › Pheochromocytoma › Illinois
Pheochromocytoma clinical trials in Illinois
3 studies for Pheochromocytoma are looking for participants at sites in Illinois.
Cities in Illinois
Belzutifan/MK-6482 for the Treatment of Advanced Pheochromocytoma/Paraganglioma (PPGL), Pancreatic Neuroendocrine Tumor (pNET), Von Hippel-Lindau (VHL) Disease-Associated Tumors, Advanced Gastrointestinal Stromal Tumor (wt GIST), or Solid Tumors With HIF-2α Related Genetic Alterations (MK-6482-015)
- Northwestern University - Robert H. Lurie Comprehensive Cancer Center ( Site 0130), Chicago
- Northwestern Medicine Cancer Center - Warrenville ( Site 0134), Warrenville
RecruitingPhase 2
Ages 12 and older · All sexes · Updated Sep 25, 2026 · NCT04924075Project: Every Child for Younger Patients With Cancer
- Rush-Copley Medical Center, Aurora
- Lurie Children's Hospital-Chicago, Chicago
- Northwestern University, Chicago
- and 16 more
RecruitingObservational study
Up to age 25 · All sexes · Updated Aug 25, 2026 · NCT02402244Targeted Alpha-Particle Therapy for Advanced Somatostatin Receptor Type 2 (SSTR2) Positive Tumors
- The University of Chicago, Chicago
RecruitingPhase 1/2
Ages 18 to 90 · All sexes · Updated May 14, 2026 · NCT05636618From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.